Form D · Pharmaceuticals
Goldfinch Bio, Inc.
Cambridge, MA · CIK 0001693198
Offering snapshot reported Jul 14, 2020 · SEC filing
- Reported sold
- $69.7M Indefinite offering
- Investors reported
- 26 Form D · investor count
- Minimum accepted
- $0 Reported outside-investor minimum
- First sale
- Jun 29, 2020 As reported in this filing
What changed?
Latest filing versus its linked predecessor, where available.
No comparable changes in the displayed metrics.
Filing history
Scroll to see all columns →
| Filed | Filing type | Reported sold | Change vs linked filing | Investors | Source |
|---|---|---|---|---|---|
| Jul 14, 2020 | Initial | $69,708,309 | No comparison | 26 | SEC filing |
| Jan 23, 2017 | Initial | $596 | No comparison | 20 | SEC filing |
Offering details
- Securities
- Equity
- Exemptions
- 06b
- Duration over one year
- No
- Business combination
- No
- Sales commissions
- $0
- Finders' fees
- $0
- Form D file number
- 021-370930
Source: Form D, filed Jul 14, 2020. Minimum accepted may differ from a standard advertised minimum.
Fund connections
No confirmed ADV fund connection is available for this issuer.
People & organizations
Current and past Form D appearances. These existing records do not establish a person's current role or uniquely identify them across issuers.
| Name | Reported role |
|---|---|
| Louis Brenner | Director |
| Abbie Celniker | Director |
| Wen Chen | Director |
| Frank Czerwiec | Executive |
| Curtis Demick | Executive |
| Neil Exter | Director |
| Joy Ghosh | Director |
| Jean Christophe Harmange | Executive |
| Anthony Johnson | Director, Executive |
| Kyle Kuvalanka | Executive |
| Frank Maddux | Director |
| Lori Rudolph Owen | Executive |
| Peter Thomson | Executive |
Issuer details
Industry: Pharmaceuticals (See others in industry)
Address:
215 First Street
Cambridge, MA, 02142
Cambridge, MA, 02142